Background The objective was to study ovarian reserve values in women of early reproductive age with polycystic ovary syndrome (PCOS) according to their phenotype. Materials and methods Two hundred women of early reproductive age with PCOS and without PCOS were studied by clinical, laboratory (hormonal), ultrasound and statistical methods. Results The anti-Müllerian hormone (AMH) index in women with PCOS with the main (A) and non-androgenic (D) phenotypes corresponded to a high level, with anovulatory (B), ovulatory (C) corresponding to a normal level. AMH in women with the main (A) phenotype differed and was higher compared with women with anovulatory (B) and ovulatory (C) phenotypes and had no differences to women with the non-androgenic (D) phenotype. No differences in the AMH level between anovulatory (B) and ovulatory (C) phenotypes have been established. Ultrasound parameters of the ovaries (volume, number of antral follicles in the section, average diameter of the follicles) of women with PCOS of the main (A), ovulatory (C) and non-androgenic (D) phenotypes were statistically significantly larger than healthy ones. With anovulatory (B) phenotype these figures did not differ from the control group. When comparing phenotypes by ultrasound parameters of the ovaries the main (A), ovulatory (C) and non-androgenic (D) phenotypes did not have any differences among themselves. Anovulatory phenotype (B) had lower ultrasound indices. Conclusion The study of indicators of ovarian reserve in women of early reproductive age with PCOS is a promising direction that will allow to more accurately determine the reproductive potential of each particular woman and influence the choice of treatment tactics.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1515/hmbci-2018-0081 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation.
N Engl J Med
January 2025
From the TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston (C.T.R., S.M.P., R.P.G., D.A.M., J.F.K., E.L.G., S.A.M., S.D.W., M.S.S.); Anthos Therapeutics, Cambridge, MA (B.H., S.P., D.B.); the Heart Rhythm Center, Taipei Veterans General Hospital and Cardiovascular Center, Taipei, Taiwan (S.-A.C.); Taichung Veterans Hospital, Taichung, Taiwan (S.-A.C.); National Yang Ming Chiao Tung University, Hsinchu, Taiwan (S.-A.C.); National Chung Hsing University, Taichung, Taiwan (S.-A.C.); St. Michael's Hospital, Unity Health Toronto, Peter Munk Cardiac Centre, University Health Network, University of Toronto, Toronto (S.G.G.); Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada (S.G.G.); the Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea (B.J.); the Department of Cardiology, Central Hospital of Northern Pest-Military Hospital, Budapest, Hungary (R.G.K.); the Heart and Vascular Center, Semmelweis University, Budapest, Hungary (R.G.K.); the Internal Cardiology Department, St. Ann University Hospital and Masaryk University, Brno, Czech Republic (J.S.); the Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland (W.W.); the Departments of Medicine and of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada (J.W.); and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada (J.W.).
Background: Abelacimab is a fully human monoclonal antibody that binds to the inactive form of factor XI and blocks its activation. The safety of abelacimab as compared with a direct oral anticoagulant in patients with atrial fibrillation is unknown.
Methods: Patients with atrial fibrillation and a moderate-to-high risk of stroke were randomly assigned, in a 1:1:1 ratio, to receive subcutaneous injection of abelacimab (150 mg or 90 mg once monthly) administered in a blinded fashion or oral rivaroxaban (20 mg once daily) administered in an open-label fashion.
Peripartum Mental Illness in Mothers With Multiple Sclerosis and Other Chronic Diseases in Ontario, Canada.
Neurology
February 2025
Schools of Pharmacy and Public Health Sciences, University of Waterloo, Ontario, Canada.
Background And Objectives: Peripartum mood and anxiety disorders constitute the most frequent form of maternal morbidity in the general population, but little is known about peripartum mental illness in mothers with multiple sclerosis (MS). We compared the incidence and prevalence of peripartum mental illness among mothers with MS, epilepsy, inflammatory bowel disease (IBD), and diabetes and women without these conditions.
Methods: Using linked population-based administrative health data from ON, Canada, we conducted a cohort study of mothers with MS, epilepsy, IBD, and diabetes and without these diseases (comparators) who had a live birth with index dates, defined as 1 year before conception, between 2002 and 2017.
Female Brain and Endocrinological Research-Veteran (FemBER-Vet) study: A study protocol for identifying endocrinological, lifestyle and psychosocial determinants of brain health outcomes in female veterans for future intervention success.
PLoS One
January 2025
Female Brain & Endocrine Health Research (FemBER) Consortium.
Background: Recent studies have demonstrated a greater risk of dementia in female veterans compared to civilians; with the highest prevalence noted for former service women with a diagnosis of psychiatric (trauma, alcoholism, depression), and/or a physical health condition (brain injury, insomnia, diabetes). Such findings highlight the need for increased and early screening of medical and psychiatric conditions, and indeed dementia, in the female veteran population. Further, they call for a better understanding of the underlying biopsychosocial mechanisms that might confer heightened risk for female veterans, to tailor preventative and interventional strategies that support brain health across the lifespan.
View Article and Find Full Text PDFEditorial Comment: Key Elements of Pelvic MRI in Assessing the Feasibility of Fertility-Sparing Treatments for Early-Stage Endometrial and Cervical Cancers.
AJR Am J Roentgenol
January 2025
Assistant Professor, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School.
[Prolonged cytopenia following third-line CAR-T therapy in a heavily chemotherapy-pretreated patient.].
Recenti Prog Med
January 2025
Fondazione Policlinico Universitario A. Gemelli Irccs, Dipartimento di Scienze di Laboratorio ed Ematologiche, Roma.
A 28-year-old woman was diagnosed with high-risk triple-expressor diffuse large B-cell lymphoma (DLBCL) (stage IV, IPI 4, CNS-IPI 5), with lymph node and extranodal involvement. The patient underwent first-line R-CHOP treatment, achieving a partial response with residual mediastinal uptake. A second-line platinum-based therapy with a transplant plan followed, resulting in stable disease; thus, she was considered refractory and started third-line therapy with CAR-T cells, receiving additional chemotherapy as bridging therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!